Research Focus

Statins, a class of cholesterol lowering drugs, are one of the most effective agents for primary and secondary preventions of CVD. Nonetheless, non-adherence to statins remains a challenge and factors contributing to non-adherence include high cost, lack of perceivable benefits and importantly, statin-associated ADRs 45. Non-adherence to statins is associated with adverse clinical outcomes and higher overall healthcare costs.

In the primary cohort (n=3,000), a genome-wide association study (GWAS) will be performed, for discovery of loci that correlate with either pharmacokinetic or symptomatic phenotypes. GWAS is an established technique for association of single nucleotide polymorphisms (SNP’s) with symptomatic or other biomarker phenotypes. In parallel with GWAS examination, whole exome sequencing will be performed to identify coding mutations.

Principal Investigator

Co-PI: Chester Drum (CVRI)

Co-Investigators: Mark Richards (CVRI), E Shyong Tai (NUHS), Mark Chan (CVRI), Jack Tan Wei Chieh (NHCS), JJ Liu (GIS)

Principal Investigator

Co-PI: Chester Drum (CVRI)

Co-Investigators: Mark Richards (CVRI), E Shyong Tai (NUHS)

Mark Chan (CVRI), Jack Tan Wei Chieh (NHCS), JJ Liu (GIS)